Ovarian cancer trials in Brazil

In Brazil 17 Also abroad 794

17 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Belo Horizonte, Curitiba, Goiânia, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Fortaleza, Itajaí, Jaú, Natal, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Belém, Belo Horizonte, Florianópolis, Lago Sul, Rio de Janeiro, Salvador, São Caetano do Sul
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Belo Horizonte, Blumenau, Jaú, Natal, Porto Alegre, Santo André, São José do Rio Preto, São Paulo
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Belo Horizonte, Porto Alegre, Rio de Janeiro
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barretos, Florianópolis, Jaú, Porto Alegre
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Enrolling by invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Where
Fortaleza, Goiânia, Londrina, Porto Alegre, Porto Velho, Rio de Janeiro, Santo André, São Paulo
Age
18 years to 51 years
People
250 worldwide
Run by
Tolmar Inc.
See details and how to joinNCT05645536
Phase 3Taking people
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Where
Porto Alegre, São Caetano do Sul, São José do Rio Preto, São José dos Campos, São Paulo, Teresina, Vitória
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Lages, Natal, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Lages, Natal, Porto Alegre, Salvador, São José do Rio Preto, São Paulo
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 1/2Taking people
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Where
Barretos, Porto Alegre, São Paulo, Sorocaba
Age
18 years and over
People
612 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT04590326 · EU 2022-501904-83-00
No phaseTaking people
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Where
São Paulo
Age
18 years and over
People
1,000 worldwide
Run by
AbbVie
See details and how to joinNCT07539844
No phaseNot yet taking people in Brazil
Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
Where
Belo Horizonte, Campo Grande, Lages, Natal, Porto Alegre, Recife, Rio de Janeiro, São Paulo
Age
18 years and over
People
320 worldwide
Run by
Latin American Cooperative Oncology Group
See details and how to joinNCT07771400
Phase 3Taking people
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Where
Barretos, Bela Vista, Curitiba, Goiânia, Natal, Porto Alegre, Porto Velho, Rio de Janeiro, São José do Rio Preto, São Paulo
Age
18 years and over
People
1,100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00
No phaseTaking people
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Where
São Paulo
Age
25 years to 50 years
People
3,000 worldwide
Run by
University Medical Center Nijmegen
See details and how to joinNCT04294927
Phase 3Taking people
Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)
Where
São Paulo
Age
18 years to 60 years
People
140
Run by
University of Sao Paulo General Hospital
See details and how to joinNCT06343870
No phaseNot yet taking people in Brazil
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Where
Recife
Age
18 years and over
People
103
Run by
Universidade Federal de Pernambuco
See details and how to joinNCT06787807